Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

10/25

Growth 2 Margin 2 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

10
AMLX Q2 2026: Avexatide Phase 3 Data Imminent as $250M Cash Runway Backs 2027 Launch Readiness
August 07, 2026
9
AMLX Q1 2026: Avexatide Phase III Completion Sets Up Pivotal Q3 Data Readout
May 07, 2026
10
Amylix Pharmaceuticals (AMLX) Q4 2025: Cash Runway Extended to 2028 as Lucidity Phase 3 Nears Key Data
March 03, 2026
10
Amylix Pharmaceuticals (AMLX) Q3 2025: Cash Position Rises to $344M as Avexitide Phase 3 Data Pushed to Q3 2026
November 06, 2025
9
AMLX Q2 2025: R&D Spend Up 17% as Avexatide Phase 3 Nears Full Enrollment
August 07, 2025
8
Amylix Pharmaceuticals (AMLX) Q1 2025: Expenses Down 82% as Pipeline Milestones Stack Up
July 06, 2025
Amylyx Pharmaceuticals (AMLX) Q4 2024: $65.5M Financing Extends Cash Runway Through 2026 Amid Pivotal Phase 3 Trial Launch
March 04, 2025
Amylx Pharmaceuticals (AMLX) Q3 2024: R&D Spend Drops 29% as Avexitide Phase III Readout Anchors Pipeline Focus
November 07, 2024
Amylix Pharmaceuticals (AMLX) Q2 2024: Avexatide Acquisition and 66% Event Reduction Signal Pipeline Reset
August 08, 2024
Amylix Pharmaceuticals (AMLX) Q1 2024: 70% Workforce Cut Resets Pipeline Focus, Cash Runway Extends to 2026
May 09, 2024
Amylix (AMLX) Q4 2023: International Revenue Jumps as U.S. ALS Patient Base Holds Steady
February 22, 2024
AMLX Q3 2023: Discontinuation Rate Hits 40%, Spotlighting Persistency Challenge Ahead of Phoenix Data
November 09, 2023
AMLX Q2 2023: Relivrio Patient Base Grows 29% as U.S. ALS Adoption Accelerates
August 10, 2023
AMLX Q1 2023: Relivrio Patient Base Doubles to 3,000, Catalyzing Early Profitability and Pipeline Expansion
May 11, 2023
AMLX Q4 2022: Relivrio Patient Base Doubles as U.S. Launch Drives Early Uptake
March 13, 2023

Browse all companies